AZTA

AzentaD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The bull case is that the May reset clears the deck: Sample Management still has resilient recurring pockets, UK Biocentre expands European sample-management capacity, liquidity remains strong, and a cleaner portfolio after B Medical plus better Multiomics execution could rebuild margins from depressed expectations.

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.4.

What can break

Automated Stores rework costs and higher excess-and-obsolete inventory reserves are already hurting gross margin and could persist if execution does not improve.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $19.00 · Bull $26.00 · Bear $14.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $26.20

Why

Momentum63 · Δ7d +6.8

Value62 · Δ7d -0.4

Sentiment22 · Δ7d -4.9

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

+6.8

Δ21d

-12.3

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.4

Δ21d

-0.2

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-4.9

Δ21d

-3.9

Why this grade

Composite grade D. Momentum 62.5 / Value 61.5 / Sentiment 21.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$1.21B

Beta

1.34

Shares Out

46.09M

P/E (TTM)

67.2

P/S (TTM)

2.77

P/FCF (TTM)

42.90

Rev YoY

+1.0%

EPS YoY

+234.9%

Gross Margin

+44.5%

Op Margin

-4.5%

Net Debt

-$283.35M

Current Ratio

2.83

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology